Extraterrestrial genome accountability governance doctrine

Introduction

The Extraterrestrial Genome Accountability Governance Doctrine is an emerging theoretical framework concerning legal responsibility for the discovery, collection, analysis, storage, modification, transmission, or possible exploitation of genetic or genome-like biological information originating outside Earth.

The concept becomes relevant if future space missions discover extraterrestrial biological material containing genetic systems, hereditary information, or molecular structures comparable to terrestrial genomes. It would raise questions concerning scientific ownership, planetary protection, biosafety, privacy, intellectual property, international responsibility, benefit-sharing, and accountability for misuse.

There is currently no reported judicial decision directly establishing an extraterrestrial genome accountability doctrine. Consequently, the doctrine must be constructed by analogy from international space law, biodiversity law, genetic-resource regulation, constitutional privacy principles, environmental law, and biotechnology jurisprudence.

Meaning of an extraterrestrial genome

A genome ordinarily refers to the genetic information of an organism. An extraterrestrial genome could therefore mean genetic or hereditary information discovered in:

• extraterrestrial microorganisms;
• biological samples returned from Mars or other celestial bodies;
• potentially living extraterrestrial organisms;
• fossilised biological material;
• extraterrestrial biological environments; or
• artificial biological systems of extraterrestrial origin.

However, the mere discovery of an unfamiliar molecule would not automatically establish that it constitutes a genome. Scientific verification would be essential.

Outer Space Treaty and international responsibility

The Outer Space Treaty, 1967 provides the fundamental legal framework.

Article I provides that exploration and use of outer space should be carried out for the benefit and in the interests of all countries.

Article II prohibits national appropriation of celestial bodies.

Article IX requires States to conduct activities so as to avoid harmful contamination of celestial bodies and adverse changes to Earth's environment resulting from the introduction of extraterrestrial matter.

These provisions create an important foundation for extraterrestrial genome governance. A State or private company could not necessarily treat a discovered extraterrestrial biological system as an ordinary commercial resource free from international obligations.

Ownership and appropriation questions

One of the most difficult issues would be determining whether a discovered extraterrestrial genome can be legally owned.

A distinction must be made between:

the extraterrestrial organism or natural biological phenomenon and a human-created invention derived from studying it.

The Outer Space Treaty prohibits national appropriation of celestial bodies, but it does not expressly establish a detailed regime governing intellectual-property rights in extraterrestrial genetic information.

Consequently, future law may need to determine whether collecting and analysing an extraterrestrial genome constitutes permissible scientific activity or an impermissible form of appropriation.

Analogy with biological-resource law

The Convention on Biological Diversity (CBD) and the Nagoya Protocol provide useful terrestrial analogies.

The CBD recognises State sovereignty over natural resources, while the Nagoya Protocol establishes principles concerning access to genetic resources and fair and equitable sharing of benefits arising from their utilisation.

These instruments do not directly apply to extraterrestrial genetic material. There is no established rule that extraterrestrial genomes automatically become subject to the CBD or Nagoya Protocol.

Nevertheless, they demonstrate an important legal policy principle: genetic resources may raise questions of access, control, scientific use, and benefit-sharing.

A future extraterrestrial regime could adapt similar principles to space resources without violating the non-appropriation principle of space law.

Accountability for sample collection

A space agency or private company collecting extraterrestrial biological material could have responsibilities concerning:

• contamination prevention;
• scientific documentation;
• sample preservation;
• secure transportation;
• laboratory containment;
• data integrity;
• reporting of significant discoveries; and
• prevention of unauthorised distribution.

If a company deliberately contaminated a sample with terrestrial genetic material, for example, the scientific and legal consequences could be substantial because the contamination could destroy the evidentiary value of the discovery.

Planetary protection

Planetary protection is central to extraterrestrial genome governance.

The COSPAR Planetary Protection Policy provides internationally recognised scientific guidance concerning contamination of extraterrestrial environments and the return of potentially hazardous material to Earth.

The governance problem has two directions:

Forward contamination: terrestrial genetic material could alter an extraterrestrial ecosystem or compromise the search for indigenous life.

Backward contamination: extraterrestrial biological material could potentially pose an unknown risk after return to Earth.

The Outer Space Treaty, Article IX provides the principal international legal basis for avoiding harmful contamination.

Precautionary principle

Scientific uncertainty surrounding extraterrestrial genomes could be profound. Authorities may not initially know whether an extraterrestrial organism is harmless, pathogenic, ecologically significant, or biologically incompatible with Earth.

The precautionary principle therefore becomes relevant.

In Vellore Citizens' Welfare Forum v. Union of India, (1996) 5 SCC 647, the Supreme Court recognised precaution as an important principle of Indian environmental law.

Although Vellore does not concern extraterrestrial biology, its reasoning provides a useful analogy: where potentially serious harm exists and scientific certainty is incomplete, reasonable preventive safeguards should not be postponed until complete certainty is achieved.

Backward contamination and public health

If an extraterrestrial genome were discovered in a returned sample, authorities might need to establish containment and biosafety procedures before distributing it to laboratories.

Relevant measures could include:

• secure sample facilities;
• controlled access;
• staged biological testing;
• independent verification;
• emergency procedures;
• specialised containment;
• detailed chain-of-custody records; and
• controlled international distribution.

The International Health Regulations (2005) could provide a comparative public-health framework for surveillance and international notification, although they do not specifically regulate extraterrestrial biological material.

Genomic information and privacy

If an extraterrestrial genome were derived from a potentially intelligent biological organism, a separate ethical and legal question could arise concerning whether the genetic information itself deserves protection.

Human genomic privacy principles provide a useful analogy.

In K.S. Puttaswamy (Retd.) v. Union of India, (2017) 10 SCC 1, the Supreme Court recognised privacy as a fundamental right linked to dignity and autonomy.

Similarly, S. and Marper v. United Kingdom, (2008) ECHR 1581 demonstrates the legal significance of genetic information in privacy law.

These cases cannot directly confer privacy rights on extraterrestrial organisms. However, if future scientific evidence demonstrated that an extraterrestrial organism possesses sophisticated cognition or social characteristics, lawmakers might need to consider whether its biological information should receive some form of special protection.

Intellectual-property implications

An extraterrestrial genome would create difficult patent questions.

Under conventional patent systems, a naturally occurring discovery is generally distinguished from a human-created invention. In Diamond v. Chakrabarty, 447 U.S. 303 (1980), the U.S. Supreme Court held that a genetically engineered microorganism could qualify for patent protection under U.S. law.

The important distinction is between:

discovering a naturally existing biological phenomenon and creating a sufficiently novel human-made invention based upon biological material.

Accordingly, a future extraterrestrial genome might not itself automatically become patentable merely because humans discovered it. However, a genuinely novel human-engineered application derived from studying that genome could raise separate patent questions under the relevant domestic law.

Scientific evidence and authenticity

Before legal rights or restrictions are imposed, the authenticity of an extraterrestrial genome would need to be established.

Courts and regulators may eventually confront disputes concerning whether biological material is genuinely extraterrestrial or contaminated.

The reliability principles discussed in Daubert v. Merrell Dow Pharmaceuticals, 509 U.S. 579 (1993) provide a useful analogy for evaluating scientific methodology.

Similarly, State of H.P. v. Jai Lal, (1999) 7 SCC 280 emphasises that expert evidence is advisory and must be evaluated by the court.

For extraterrestrial genomic disputes, relevant evidence could include:

• sequencing data;
• laboratory controls;
• contamination records;
• independent replication;
• chain-of-custody evidence; and
• peer-reviewed scientific analysis.

Private companies and corporate accountability

Commercial space companies could potentially become major participants in extraterrestrial biological research. This creates the need for continuing governmental supervision.

The Outer Space Treaty places international responsibility upon States for national space activities, including activities conducted by non-governmental entities.

Therefore, a State may need to ensure that private operators comply with:

• planetary-protection requirements;
• sample-handling standards;
• reporting obligations;
• biosafety procedures; and
• international commitments.

Commercial confidentiality should not automatically override legitimate biosecurity or scientific-integrity requirements.

International benefit-sharing

If an extraterrestrial genome led to a commercially valuable medicine, industrial process, or biotechnology platform, questions could arise about who should receive the resulting benefits.

Possible beneficiaries could include:

• the company that discovered it;
• the launching State;
• participating States;
• international scientific institutions; or
• humanity collectively.

Existing space law does not provide a comprehensive benefit-sharing mechanism specifically for extraterrestrial genetic discoveries.

The Moon Agreement contains stronger language concerning the Moon's natural resources as the common heritage of mankind, but its acceptance is limited compared with the Outer Space Treaty.

This illustrates the need for future international rules if extraterrestrial biological resources acquire substantial commercial significance.

Liability for misuse or contamination

Accountability could arise where an actor:

• intentionally contaminates an extraterrestrial sample;
• releases potentially hazardous biological material;
• falsifies genomic research;
• violates containment rules;
• exports samples without authorisation; or
• conceals a serious biological hazard.

Possible consequences could include domestic regulatory sanctions, civil liability, contractual consequences, or international responsibility, depending upon the applicable legal framework.

The Liability Convention, 1972 provides a broader framework concerning liability for damage caused by space objects, although its application to biological harm caused by extraterrestrial genomic material remains legally uncertain.

Governance principles

A future extraterrestrial genome regime could be based on several principles:

• Non-appropriation: discovery should not automatically amount to sovereign ownership.
• Scientific integrity: samples should be protected from contamination.
• Precaution: uncertain but potentially serious risks should be managed proactively.
• Containment: potentially hazardous material should remain securely controlled.
• Transparency: major biological discoveries should be independently verified.
• Accountability: private and governmental actors should remain responsible for their activities.
• Benefit-sharing: future commercial exploitation may require internationally agreed mechanisms.

Conclusion

The Extraterrestrial Genome Accountability Governance Doctrine is presently a theoretical and emerging legal concept rather than an established judicial doctrine. No court has yet determined ownership, legal status, or liability concerning a genuinely extraterrestrial genome.

Its strongest existing foundations are found in the Outer Space Treaty, Article IX, COSPAR planetary-protection standards, international public-health principles, biodiversity and genetic-resource law, and domestic constitutional and environmental jurisprudence.

Cases such as Puttaswamy, Vellore Citizens' Welfare Forum, Diamond v. Chakrabarty, Daubert, and State of H.P. v. Jai Lal provide useful analogies, but none directly decides extraterrestrial genome disputes.

The central principle should be that the discovery of extraterrestrial genetic material creates responsibilities before it creates commercial opportunities. Any future governance regime should prioritise scientific verification, planetary protection, containment, responsible research, international accountability, and carefully regulated commercial use while respecting the non-appropriation principles of international space law.